Ray Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$125M
- Investors
-
12
Ray Therapeutics General Information
Description
Developer of optogenetic gene therapies designed to restore visual function in individuals affected by degenerative retinal diseases. The company offers a bioengineered therapeutic platform that utilizes viral vectors to deliver light-sensitive proteins to surviving retinal neurons, enabling patients with retinitis pigmentosa and other blinding conditions to regain functional vision and improve daily independence.
Contact Information
Website
www.raytherapeutics.comCorporate Office
- 2607 7th Street
- Suite B
- Berkeley, CA 94710
- United States
Corporate Office
- 2607 7th Street
- Suite B
- Berkeley, CA 94710
- United States
Ray Therapeutics Timeline
Ray Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 21-Apr-2026 | $125M | Completed | Clinical Trials - General | ||
| 4. Grant | 25-Apr-2025 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 15-May-2023 | Completed | Clinical Trials - General | |||
| 2. Grant | 26-Apr-2022 | $4M | $6M | Completed | Clinical Trials - General | |
| 1. Seed Round | 04-Jan-2022 | $6M | $6M | Completed | Clinical Trials - General |
Ray Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 7,500,000 | $0.000100 | 8% | $0.8 | $0.8 | 1x | $0.8 | 5.04% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ray Therapeutics Comparisons
Industry
Financing
Details
Ray Therapeutics Competitors (1)
One of Ray Therapeutics’s competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA |
Ray Therapeutics Patents
Ray Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026232050-A1 | Methods and compositions to assess potency of post-transduction channelrhodopsin | Pending | 02-May-2025 | ||
| WO-2026085387-A1 | Multi-luminance mobility test for the assessment of vision | Pending | 18-Oct-2024 | ||
| AU-2024221317-A1 | Gene therapy compositions and methods for treating diseases of the retina | Pending | 17-Feb-2023 | ||
| EP-4665750-A1 | Gene therapy compositions and methods for treating diseases of the retina | Pending | 17-Feb-2023 | ||
| US-20250387513-A1 | Gene therapy compositions and methods for treating diseases of the retina | Pending | 17-Feb-2023 | A61K48/005 |
Ray Therapeutics Signals
Ray Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Franklin Templeton (Asia Pacific) | Asset Manager | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Marshall Wace | Hedge Fund | Minority |
Ray Therapeutics FAQs
-
When was Ray Therapeutics founded?
Ray Therapeutics was founded in 2021.
-
Where is Ray Therapeutics headquartered?
Ray Therapeutics is headquartered in Berkeley, CA.
-
What is the size of Ray Therapeutics?
Ray Therapeutics has 33 total employees.
-
What industry is Ray Therapeutics in?
Ray Therapeutics’s primary industry is Drug Discovery.
-
Is Ray Therapeutics a private or public company?
Ray Therapeutics is a Private company.
-
What is the current valuation of Ray Therapeutics?
The current valuation of Ray Therapeutics is .
-
What is Ray Therapeutics’s current revenue?
The current revenue for Ray Therapeutics is .
-
How much funding has Ray Therapeutics raised over time?
Ray Therapeutics has raised $231M.
-
Who are Ray Therapeutics’s investors?
Adage Capital Management, Franklin Templeton (Asia Pacific), Invus (Private Equity), Janus Henderson Investors, and Marshall Wace are 5 of 12 investors who have invested in Ray Therapeutics.
-
Who are Ray Therapeutics’s competitors?
Adverum Biotechnologies is a competitor of Ray Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process